ArticleSurgical endoscopy2026
Long-term and second recurrence following curative ESD for synchronous multiple early gastric neoplasia: a single-center cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSynchronous multiple early gastric neoplasia (SM-EGN) is increasingly detected with advanced endoscopic imaging. However, long-term recurrence dynamics after curative endoscopic submucosal dissection (ESD), particularly second recurrence, remain insufficiently defined.
methodsWe retrospectively analyzed 987 patients who underwent ESD for early gastric neoplasia between 2012 and 2024, including 91 SM-EGN and 896 solitary cases. Among 766 patients with curative resection and ≥ 1 year follow-up, clinical outcomes and recurrence patterns were compared. Logistic regression identified independent predictors of recurrence, and Kaplan-Meier analysis assessed long-term outcomes.
resultsSM-EGN patients were older, more often male, and had higher rates of prior malignancy and family history. Procedure time was longer for SM-EGN (116.8 vs 80.8 min, p < 0.0001), but complication rates were similar. SM-EGN patients had a higher recurrence rate (11.7% vs. 4.8%, p = 0.011) and a higher rate of second recurrence (3.9% vs. 0.7%, p = 0.033). Multivariate regression identified SM-EGN as an independent predictor of recurrence (OR 2.162, p = 0.048). Among recurrent patients, no independent predictors of second recurrence were found, and OS/DFS did not differ between single and double recurrence. In curative patients with ≥ 1 year follow-up, SM-EGN showed higher synchronous (p = 0.019) and metachronous (p = 0.027) recurrence, and shorter DFS to both first (p = 0.002) and second recurrence (p = 0.041).
conclusionsSM-EGN confers a persistently higher recurrence risk after curative ESD, consistent with the phenomenon of field cancerization. No significant difference in survival was observed in the limited second recurrence cohort, likely due to intensive monitoring and timely intervention. That hints to us that SM-EGN patients require lifelong, risk-adapted surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.